Genzyme Australasia Pty Ltd

20 PBAC submissions on file, active 2006–2015. 40% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Alglucosidase alfa
  Metabolic · Not recommended · 2013—
• Sevelamer hydrochloride
  Renal · Recommended with restriction · 2007—
• Alemtuzumab
  Neurology · Not recommended · 2018—
• Plerixafor
  Haematology · Recommended with restriction · 2013other sponsor
• Teriflunomide
  Neurology · Not recommended · 2016—
• Thyrotropin alfa
  Endocrinology · Recommended with restriction · 2007—
• Eliglustat
  Metabolic · Recommended with restriction · 2015—
• Hylan g-f 20
  Musculo-skeletal · Not recommended · 2006—
• Idursulfase
  Rare disease · Not recommended · 2007—

Therapy area mix

Activity by year

2006 (4) · 2007 (3) · 2008 (1) · 2009 (1) · 2010 (2) · 2011 (2) · 2012 (2) · 2013 (2) · 2014 (2) · 2015 (1)

Rejection patterns

Across 11 Not recommended decisions on file.

• 1×unacceptably high incremental cost-effectiveness ratio
• 1×insufficient certainty that drug substantially extends lifespan in late-onset Pompe disease
• 1×non-randomised observational data subject to residual confounding and unmeasured confounders
• 1×heterogeneous late-onset population
• 1×modest survival differences compared to infantile-onset disease